Sudo Biosciences

About:

Sudo Biosciences is a biopharma company that designs and develops medicines that target the tyrosine kinase 2 (TYK2) pseudokinase domain.

Website: https://www.sudobio.com

Top Investors: TPG, Enavate Sciences, Dementia Discovery Fund, Frazier Life Sciences, UPMC Enterprises

Description:

Sudo Biosciences is a biopharmaceutical company that designs and develops medicines that target the tyrosine kinase 2 (TYK2) pseudokinase domain, a crucial mediator in cytokine signaling pathways that have been linked to a broad range of immune-mediated inflammatory conditions. Its pipeline of next-generation TYK2 inhibitors includes a potential brain-penetrant candidate for treating multiple sclerosis and neurodegenerative diseases with underlying neuroinflammation and a potential topical candidate for immune-mediated dermatologic diseases. It helps patients receive the cure or the treatment of multiple sclerosis and neurodegenerative diseases with underlying neuroinflammation at a competitive cost.